PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-19.78%
Both yoy net incomes decline, with AGEN at -7.05%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
2.78%
D&A growth well above AGEN's 3.29%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
37.14%
SBC growth well above AGEN's 6.66%. Michael Burry would flag major dilution risk vs. competitor’s approach.
172.06%
Well above AGEN's 182.82% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
172.06%
Some yoy usage while AGEN is negative at -27.09%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-10743.19%
Both negative yoy, with AGEN at -26.63%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-10.71%
Negative yoy CFO while AGEN is 15.38%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.75%
We cut debt repayment yoy while AGEN is 44.41%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.18%
Negative yoy issuance while AGEN is 233.56%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.